Wall Street brokerages expect Atara Biotherapeutics Inc (NASDAQ:ATRA) to announce ($0.92) earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have made estimates for Atara Biotherapeutics’ earnings. The lowest EPS estimate is ($0.92) and the highest is ($0.91). Atara Biotherapeutics posted earnings of ($0.66) per share during the same quarter last year, which indicates a negative year over year growth rate of 39.4%. The business is scheduled to announce its next quarterly earnings results on Monday, August 14th.
On average, analysts expect that Atara Biotherapeutics will report full-year earnings of ($3.93) per share for the current fiscal year, with EPS estimates ranging from ($4.16) to ($3.70). For the next year, analysts anticipate that the firm will post earnings of ($4.25) per share, with EPS estimates ranging from ($4.60) to ($3.90). Zacks Investment Research’s earnings per share calculations are an average based on a survey of research firms that follow Atara Biotherapeutics.
Atara Biotherapeutics (NASDAQ:ATRA) last posted its quarterly earnings results on Thursday, March 9th. The biotechnology company reported ($0.63) EPS for the quarter, beating the consensus estimate of ($0.98) by $0.35.
ATRA has been the topic of a number of research analyst reports. Citigroup Inc set a $10.00 price objective on shares of Atara Biotherapeutics and gave the stock a “sell” rating in a report on Thursday, March 16th. Canaccord Genuity reiterated a “buy” rating and issued a $47.00 price target on shares of Atara Biotherapeutics in a research note on Friday, April 21st. Finally, Zacks Investment Research lowered shares of Atara Biotherapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, May 9th. Three research analysts have rated the stock with a sell rating and three have given a buy rating to the company. The company has an average rating of “Hold” and a consensus price target of $24.00.
WARNING: This report was first published by Markets Daily and is owned by of Markets Daily. If you are reading this report on another site, it was illegally stolen and reposted in violation of United States & international copyright & trademark laws. The legal version of this report can be viewed at https://www.themarketsdaily.com/2017/05/20/0-92-eps-expected-for-atara-biotherapeutics-inc-atra-this-quarter.html.
In related news, CEO Isaac E. Ciechanover sold 30,800 shares of Atara Biotherapeutics stock in a transaction dated Friday, March 17th. The shares were sold at an average price of $19.38, for a total transaction of $596,904.00. Following the completion of the sale, the chief executive officer now owns 725,951 shares of the company’s stock, valued at approximately $14,068,930.38. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Isaac E. Ciechanover sold 4,800 shares of Atara Biotherapeutics stock in a transaction dated Thursday, May 18th. The stock was sold at an average price of $14.91, for a total transaction of $71,568.00. Following the sale, the chief executive officer now directly owns 731,859 shares of the company’s stock, valued at approximately $10,912,017.69. The disclosure for this sale can be found here. In the last three months, insiders sold 142,958 shares of company stock valued at $2,630,542. Insiders own 16.10% of the company’s stock.
Several hedge funds have recently made changes to their positions in the company. 12 West Capital Management LP bought a new stake in shares of Atara Biotherapeutics during the fourth quarter valued at approximately $5,662,000. Norges Bank bought a new stake in shares of Atara Biotherapeutics during the fourth quarter valued at approximately $4,031,000. Artal Group S.A. increased its stake in shares of Atara Biotherapeutics by 122.2% in the fourth quarter. Artal Group S.A. now owns 500,000 shares of the biotechnology company’s stock valued at $7,100,000 after buying an additional 275,000 shares during the last quarter. Arrowpoint Asset Management LLC increased its stake in shares of Atara Biotherapeutics by 18.2% in the fourth quarter. Arrowpoint Asset Management LLC now owns 1,560,612 shares of the biotechnology company’s stock valued at $22,161,000 after buying an additional 240,285 shares during the last quarter. Finally, State Street Corp increased its stake in shares of Atara Biotherapeutics by 62.8% in the fourth quarter. State Street Corp now owns 600,521 shares of the biotechnology company’s stock valued at $8,526,000 after buying an additional 231,541 shares during the last quarter. 77.48% of the stock is owned by institutional investors and hedge funds.
Atara Biotherapeutics (NASDAQ:ATRA) traded up 0.33% during trading on Monday, hitting $15.15. 164,841 shares of the stock traded hands. Atara Biotherapeutics has a one year low of $12.45 and a one year high of $25.73. The company’s 50 day moving average is $16.87 and its 200 day moving average is $16.86. The company’s market capitalization is $440.70 million.
About Atara Biotherapeutics
Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Atara Biotherapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.